5' Nucleotidase - Pipeline Review, H2 2019
5' Nucleotidase - Pipeline Review, H2 2019
SUMMARY
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 11 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Renal Cell Carcinoma, Sarcomas, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
The latest report 5' Nucleotidase - Pipeline Review, H2 2019, outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides.
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 11 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Metastatic Breast Cancer, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Non-Small Cell Lung Carcinoma, Renal Cell Carcinoma, Sarcomas, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.
The latest report 5' Nucleotidase - Pipeline Review, H2 2019, outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development
Arcus Biosciences Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec SE
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
Merck & Co Inc
Novartis AG
ORIC Pharmaceuticals Inc
Phanes Therapeutics Inc
Selvita SA
Shanghai Henlius Biotech Inc
Xcella Biosciences Inc
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles
AB-680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CD73 for Non-Small Cell Lung Cancer and Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody1 to Inhibit CD73 for Non-Small Cell Lung Cancer and Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986179 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-708 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + oleclumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HLX-23 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-1B3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Non Small Cell Lung Cancer and Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Non Small Cell Lung Cancer and Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NZV-930 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oleclumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJ-4309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJL-1D5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development
Arcus Biosciences Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec SE
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
Merck & Co Inc
Novartis AG
ORIC Pharmaceuticals Inc
Phanes Therapeutics Inc
Selvita SA
Shanghai Henlius Biotech Inc
Xcella Biosciences Inc
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles
AB-680 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CD73 for Non-Small Cell Lung Cancer and Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody1 to Inhibit CD73 for Non-Small Cell Lung Cancer and Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986179 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-708 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
durvalumab + oleclumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HLX-23 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-1B3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Non Small Cell Lung Cancer and Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Non Small Cell Lung Cancer and Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NZV-930 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oleclumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ADORA2A and CD73 for Oncology 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CD73 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJ-4309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJL-1D5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products
5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arcus Biosciences Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Calithera Biosciences Inc, H2 2019
Pipeline by Corvus Pharmaceuticals Inc, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by Innate Pharma SA, H2 2019
Pipeline by InteRNA Technologies BV, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by ORIC Pharmaceuticals Inc, H2 2019
Pipeline by Phanes Therapeutics Inc, H2 2019
Pipeline by Selvita SA, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Xcella Biosciences Inc, H2 2019
Dormant Projects, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arcus Biosciences Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Calithera Biosciences Inc, H2 2019
Pipeline by Corvus Pharmaceuticals Inc, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by I-Mab Biopharma Co Ltd, H2 2019
Pipeline by Innate Pharma SA, H2 2019
Pipeline by InteRNA Technologies BV, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by ORIC Pharmaceuticals Inc, H2 2019
Pipeline by Phanes Therapeutics Inc, H2 2019
Pipeline by Selvita SA, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Xcella Biosciences Inc, H2 2019
Dormant Projects, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Arcus Biosciences Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec SE
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
Merck & Co Inc
Novartis AG
ORIC Pharmaceuticals Inc
Phanes Therapeutics Inc
Selvita SA
Shanghai Henlius Biotech Inc
Xcella Biosciences Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Arcus Biosciences Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Corvus Pharmaceuticals Inc
Evotec SE
I-Mab Biopharma Co Ltd
Innate Pharma SA
InteRNA Technologies BV
Merck & Co Inc
Novartis AG
ORIC Pharmaceuticals Inc
Phanes Therapeutics Inc
Selvita SA
Shanghai Henlius Biotech Inc
Xcella Biosciences Inc
